Mitchell V. Mathis, MD

The recent FDA approval of aripiprazole tablets with sensor met with a myriad of reactions, including concerns about patient privacy and autonomy. In this Perspectives article, authors from the...

In 2016, pimavanserin became the only FDA-approved treatment for hallucinations and delusions associated with Parkinson's disease psychosis. This article describes the regulatory and clinical issues important to the FDA's...